Category

Archive for the 'OPINION' Category

a story: the end of the middle…

( OPINION )

I think I’ll borrow a literary device from a couple of favorites: T.S. Eliot in East Coker and John Fowles in The French Lieutenant’s Woman. It’s where the author jumps out of his story and speaks in the first person with the reader about his thoughts while he’s writing, then returns to the thread of […]

a story: starting in the middle…

( OPINION )

I’m picking up the thread of a story in the middle, because I didn’t realize it was a story with installments until I was well into it. It started with December’s American Journal of Psychiatry that had two Publicly funded Clinical Trials that looked like Infommercials [Experommercials] to me, one being about augmenting antidepressants with […]

happy holidays!…

( OPINION )

a postscript…

( OPINION )

Well, I can’t seem to let this topic lie. After my last two posts, I ran across a letter to the editor in the American Journal of Psychiatry from Dr. Bernard Carroll, a frequent commenter here, written back in 2009 in response to the meta-analysis by Nelson and Popakostas [Atypical Antipsychotic Augmentation in Major Depressive […]

extending the risk…

( OPINION )

Continued from a worksheet post… In April 2015, the FDA approved a new Atypical Antipsychotic, Brexpiprazole [Rexulti®]. Around the same time, there were two articles about the Brexpiprazole clinical trials, both released on-line ahead of print in prominent journals [see the spice must flow…]. But there were some odd things about those articles. Each one […]

a worksheet post…

( OPINION )

In the 1970s, no psychiatrist worth their salt couldn’t draw the NIMH Memorial Neuron and sketch in the receptors and re·uptake pathways. Back then, it was catecholamines, dopamine, but later came serotonin. I haven’t seen anybody do that for years. I guess people fled when confronted about the phrase chemical imbalance and other bio·hypotheses that […]

the extra mile…

( OPINION )

The topic here is augmentation with Atypical Antipsychotics in treatment resistant depression [once again], but it’s also about meta-analyses in general. In my recent in the land of sometimes[3]…, I was looking at the techniques used in making the forest plots now widely used in meta-analyses. It came to mind as I was comparing these […]

and throw away the key…

( OPINION )

‘Pharma Bro’ Martin Shkreli arrested for securities fraud

in the land of sometimes[4]…

( OPINION )

The effect of regression to the mean in epidemiologic and clinical studies. by Davis CE. American Journal of Epidemiology. 1976 104[5]:493-498. "Regression to the mean is the phrase used to identify the phenomenon that a variable that is extreme on its first measurement will tend to be closer to the center of the distribution for […]

[again]…

( OPINION )

Clinical Outcome After Antipsychotic Treatment Discontinuation in Functionally Recovered First-Episode Nonaffective Psychosis Individuals: A 3-Year Naturalistic Follow-Up Study by Jacqueline Mayoral-van Son, MD; Victor Ortiz-Garcia de la Foz, VTE; Obdulia Martinez-Garcia, PhD; Teresa Moreno, MD; Maria Parrilla-Escobar, MD; Elsa M. Valdizan, MD, PhDc; and Benedicto Crespo-Facorro, MD, PhD Journal of Clinical Psychiatry. Published online 12/08/2015 […]